BDX - Becton Dickinson & Company

NYSE · Healthcare · Medical Instruments & Supplies

$154.51

Market Closed

End of day · Apr 2, 2026, 12:00 AM

Active

Resolved

Bull

Bear

About

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

https://www.bd.com

BDX - Becton Dickinson & Company

Healthcare

This one's been absolutely pummeled in the last couple months down from the 200s to the low 150s now. It’s rare to see BDX drop this hard, but I think the market’s starting to price in more pessimism than is actually warranted. The setup here is interesting if you have some patience and aren’t expecting fireworks overnight. BDX is still a core medical devices player with diversified revenue streams across diagnostics, medication management, and biosciences. Even with cost pressures, their hospital contracts and consumables remain sticky. I’m seeing a lot of concern over margin compression lately, especially after their recent guidance cut, but the underlying demand drivers aging demographics, recurring supply contracts, and a backlog that’s still clearing from last year are all intact. That’s not the kind of thing that just evaporates because a couple quarters go sideways. Granted, the risk here is that management has a tendency to sandbag and then under-deliver, so a second guidance cut would hammer the shares further. But if you go back and look at the last few years, BDX has usually managed to stabilize margins after big resets. If they can put up even a modest beat on next quarter’s operating margins, I think we’ll see a relief rally. The next earnings print is the big catalyst, and if supply chain and margin trends show improvement, the rerating could be sharp. I’m targeting 177.05 in the next 10 weeks. No need to get greedy, just betting on mean reversion and a little operational execution. Not a moonshot, but a solid risk/reward if you want some defensive healthcare exposure while the market’s jittery elsewhere.

Entry

$154.13

Above

$177.05

Jun 1, 2026

Karma

122 to 17261

Bullish

Open

Vote